Chemokines, a family of small secreted chemotactic cytokines, and their G protein-coupled seven transmembrane spanning receptors control the migratory patterns, positioning and cellular interactions of immune cells. The levels of chemokines and their receptors are increased in the blood and within inflamed tissue of patients with rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, vasculitis or idiopathic inflammatory myopathies. Chemokine ligand–receptor interactions control the recruitment of leukocytes into tissue, which are central to the pathogenesis of these rheumatic diseases. Although the blockade of various chemokines and chemokine receptors has yielded promising results in preclinical animal models of rheumatic diseases, human clinical trials have, in general, been disappointing. However, there have been glimmers of hope from several early-phase clinical trials that suggest that sufficiently blocking the relevant chemokine pathway might in fact have clinical benefits in rheumatic diseases. Hence, the chemokine system remains a promising therapeutic target for rheumatic diseases and requires further study.
Chemokines are a large family of secreted chemotactic cytokines that control the recruitment of immune cells into tissue and their cellular interactions once in tissue.
Chemokine receptors are G protein-coupled seven transmembrane spanning proteins that are expressed on immune cells and regulate their migration and cell–cell interactions.
Concentrations of chemokines are increased in the blood and tissues of patients with rheumatic diseases, suggesting their involvement in the pathogenesis of these diseases and highlighting them as therapeutic targets.
Preclinical animal models of rheumatic diseases show the important functional roles of the chemokine system in the pathogenesis of these diseases.
Unfortunately, the majority of clinical trials testing the efficacy of chemokine and chemokine receptor inhibitors have failed to show meaningful clinical benefit.
However, several clinical studies have shown promise and suggest that targeting the relevant chemokine system and ensuring complete inhibition at all times might be needed for therapeutic benefit.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Griffith, J. W., Sokol, C. L. & Luster, A. D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659–702 (2014).
Szekanecz, Z. & Koch, A. E. Successes and failures of chemokine-pathway targeting in rheumatoid arthritis. Nat. Rev. Rheumatol. 12, 5–13 (2016).
Reynolds, J. A. et al. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res. Ther. 20, 173 (2018).
Clark, K. E. et al. Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis. Arthritis Res. Ther. 17, 73 (2015).
Berti, A. et al. Brief report: circulating cytokine profiles and antineutrophil cytoplasmic antibody specificity in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 70, 1114–1121 (2018).
Reed, A. M. et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 64, 4078–4086 (2012).
McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011).
Komano, Y. et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J. Rheumatol. 38, 1258–1264 (2011).
Ogata, A., Kato, Y., Higa, S. & Yoshizaki, K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod. Rheumatol. 29, 258–267 (2019).
Chang, M. H. & Nigrovic, P. A. Antibody-dependent and -independent mechanisms of inflammatory arthritis. JCI Insight 4, 125278 (2019).
Monach, P. A., Mathis, D. & Benoist, C. The K/BxN arthritis model. Curr. Protoc. Immunol. 81, 15.22.1–15.22.12 (2008).
Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 1269–1275 (2007).
Khachigian, L. M. Collagen antibody-induced arthritis. Nat. Protoc. 1, 2512–2516 (2006).
Matsumoto, I., Staub, A., Benoist, C. & Mathis, D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 286, 1732–1735 (1999).
Kim, N. D., Chou, R. C., Seung, E., Tager, A. M. & Luster, A. D. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J. Exp. Med. 203, 829–835 (2006).
Nanki, T. et al. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum. 52, 3004–3014 (2005).
Meeuwisse, C. M. et al. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum. 63, 1265–1273 (2011).
Endo, H., Akahoshi, T., Takagishi, K., Kashiwazaki, S. & Matsushima, K. Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine Cytokine Res. 10, 245–252 (1991).
Watanabe, K. et al. Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum. 62, 3211–3220 (2010).
Yellin, M. et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 64, 1730–1739 (2012).
Nanki, T. et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 46, 2878–2883 (2002).
Koch, A. E. et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J. Clin. Invest. 94, 1012–1018 (1994).
Pandya, J. M. et al. Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. Arthritis Res. Ther. 19, 20 (2017).
Haringman, J. J., Smeets, T. J., Reinders-Blankert, P. & Tak, P. P. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann. Rheum. Dis. 65, 294–300 (2006).
Chou, R. C. et al. Lipid-cytokine-chemokine cascade drives neutrophil recruitment in a murine model of inflammatory arthritis. Immunity 33, 266–278 (2010).
Isozaki, T. et al. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: studies in mice with K/BxN serum-induced arthritis. Arthritis Rheum. 65, 1736–1746 (2013).
Zheng, B. et al. CXCL13 neutralization reduces the severity of collagen-induced arthritis. Arthritis Rheum. 52, 620–626 (2005).
Jacobs, J. P. et al. Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis Rheum. 62, 1921–1932 (2010).
Yokoyama, W. et al. Abrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of mice. Arthritis Res. Ther. 16, 445 (2014).
Barnes, D. A. et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J. Clin. Invest. 101, 2910–2919 (1998).
Garcia-Vicuna, R. et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. 50, 3866–3877 (2004).
Haringman, J. J., Ludikhuize, J. & Tak, P. P. Chemokines in joint disease: the key to inflammation? Ann. Rheum. Dis. 63, 1186–1194 (2004).
Takayasu, A. et al. CCL18 activates fibroblast-like synoviocytes in patients with rheumatoid arthritis. J. Rheumatol. 40, 1026–1028 (2013).
Pickens, S. R. et al. Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum. 63, 914–922 (2011).
Nanki, T. et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J. Immunol. 173, 7010–7016 (2004).
Shi, K. et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J. Immunol. 166, 650–655 (2001).
Rump, L., Mattey, D. L., Kehoe, O. & Middleton, J. An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium. Cytokine 97, 133–140 (2017).
Miyabe, Y. et al. Complement C5a receptor is the key initiator of neutrophil adhesion igniting immune complex-induced arthritis. Sci. Immunol. 2, eaaj2195 (2017).
Koch, A. E. et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J. Immunol. 147, 2187–2195 (1991).
Li, J. L. et al. Neutrophils self-regulate immune complex-mediated cutaneous inflammation through CXCL2. J. Invest. Dermatol. 136, 416–424 (2016).
Lee, J. H. et al. Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis. Arthritis Res. Ther. 19, 163 (2017).
Armas-Gonzalez, E. et al. Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis. Arthritis Res. Ther. 20, 114 (2018).
Moschovakis, G. L. et al. T cell specific CXCR5 deficiency prevents rheumatoid arthritis. Sci. Rep. 7, 8933 (2017).
Kraan, M. C. et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res. 3, 65–71 (2001).
Nanki, T. et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 11, R149 (2009).
Matsumoto, N. et al. A novel alpha9 integrin ligand, XCL1/lymphotactin, is involved in the development of murine models of autoimmune diseases. J. Immunol. 199, 82–90 (2017).
Patterson, A. M. et al. Differential binding of chemokines to macrophages and neutrophils in the human inflamed synovium. Arthritis Res. 4, 209–214 (2002).
Ruth, J. H. et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum. 44, 2750–2760 (2001).
Wengner, A. M. et al. CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum. 56, 3271–3283 (2007).
Manzo, A. et al. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum. 58, 3377–3387 (2008).
Ruth, J. H. et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum. 54, 765–778 (2006).
Petit, I., Jin, D. & Rafii, S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 28, 299–307 (2007).
Ko, T. M. et al. CXCL10/IP-10 is a biomarker and mediator for Kawasaki disease. Circ. Res. 116, 876–883 (2015).
Wang, C. R., Liu, M. F., Huang, Y. H. & Chen, H. C. Up-regulation of XCR1 expression in rheumatoid joints. Rheumatology 43, 569–573 (2004).
Pickens, S. R. et al. Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesis. Arthritis Rheum. 64, 2471–2481 (2012).
Chen, Z. et al. Characterising the expression and function of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis. Ann. Rheum. Dis. 74, 1898–1906 (2015).
Smith, E. et al. Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synovium. Arthritis Rheum. 58, 1968–1973 (2008).
Patterson, A. M., Siddall, H., Chamberlain, G., Gardner, L. & Middleton, J. Expression of the Duffy antigen/receptor for chemokines (DARC) by the inflamed synovial endothelium. J. Pathol. 197, 108–116 (2002).
Baldwin, H. M. et al. Elevated ACKR2 expression is a common feature of inflammatory arthropathies. Rheumatology 56, 1607–1617 (2017).
Miyabe, Y., Miyabe, C., Mani, V., Mempel, T. R. & Luster, A. D. Atypical complement receptor C5aR2 transports C5a to initiate neutrophil adhesion and inflammation. Sci. Immunol. 4, eaav5951 (2019).
Klimatcheva, E. et al. CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol. 16, 6 (2015).
Ogata, H., Takeya, M., Yoshimura, T., Takagi, K. & Takahashi, K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol. 182, 106–114 (1997).
Angelini, A. et al. Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. Nat. Commun. 9, 1461 (2018).
Kim, B. et al. JN-2, a C-X-C motif chemokine receptor 3 antagonist, ameliorates arthritis progression in an animal model. Eur. J. Pharmacol. 823, 1–10 (2018).
Talbot, J. et al. CCR2 expression in neutrophils plays a critical role in their migration into the joints in rheumatoid arthritis. Arthritis Rheumatol. 67, 1751–1759 (2015).
Amat, M. et al. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br. J. Pharmacol. 149, 666–675 (2006).
Brodmerkel, C. M. et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J. Immunol. 175, 5370–5378 (2005).
Vierboom, M. P. et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum. 52, 627–636 (2005).
Bonelli, M. et al. CCR6 controls autoimmune but not innate immunity-driven experimental arthritis. J. Cell Mol. Med. 22, 5278–5285 (2018).
Moschovakis, G. L. et al. The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy. Cell Mol. Immunol. 16, 791–799 (2018).
Min, S. H. et al. Pharmacological targeting reveals distinct roles for CXCR2/CXCR1 and CCR2 in a mouse model of arthritis. Biochem. Biophys. Res. Commun. 391, 1080–1086 (2010).
Slauenwhite, D., Gebremeskel, S., Doucette, C. D., Hoskin, D. W. & Johnston, B. Regulation of cytokine polarization and T cell recruitment to inflamed paws in mouse collagen-induced arthritis by the chemokine receptor CXCR6. Arthritis Rheumatol. 66, 3001–3012 (2014).
Haringman, J. J. et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54, 2387–2392 (2006).
Haringman, J. J., Kraan, M. C., Smeets, T. J., Zwinderman, K. H. & Tak, P. P. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 715–721 (2003).
Tak, P. P. et al. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann. Rheum. Dis. 72, 337–344 (2013).
Vergunst, C. E. et al. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum. 60, 3572–3581 (2009).
Vergunst, C. E. et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 58, 1931–1939 (2008).
van Kuijk, A. W. et al. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann. Rheum. Dis. 69, 2013–2016 (2010).
Gerlag, D. M. et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 62, 3154–3160 (2010).
Fleishaker, D. L. et al. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res. Ther. 14, R11 (2012).
Tanaka, Y. et al. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Mod. Rheumatol. 28, 58–65 (2018).
Lebre, M. C. et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. PLOS ONE 6, e21772 (2011).
Dairaghi, D. J. et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clin. Pharmacol. Ther. 89, 726–734 (2011).
Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110–2121 (2011).
Celhar, T. & Fairhurst, A. M. Modelling clinical systemic lupus erythematosus: similarities, differences and success stories. Rheumatology 56, i88–i99 (2017).
Theofilopoulos, A. N. & Dixon, F. J. Murine models of systemic lupus erythematosus. Adv. Immunol. 37, 269–390 (1985).
Perry, D., Sang, A., Yin, Y., Zheng, Y. Y. & Morel, L. Murine models of systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 271694 (2011).
Watson, M. L. et al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci. J. Exp. Med. 176, 1645–1656 (1992).
Andrews, B. S. et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148, 1198–1215 (1978).
Fang, C., Luo, T. & Lin, L. The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus: a STROBE-compliant article. Med. 96, e8675 (2017).
Worthmann, K. et al. Pathogenetic role of glomerular CXCL13 expression in lupus nephritis. Clin. Exp. Immunol. 178, 20–27 (2014).
Sun, X. et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29, 709–722 (2010).
Hrycek, E., Franek, A., Blaszczak, E., Dworak, J. & Hrycek, A. Serum levels of selected chemokines in systemic lupus erythematosus patients. Rheumatol. Int. 33, 2423–2427 (2013).
Steinmetz, O. M. et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J. Immunol. 183, 4693–4704 (2009).
Ferreira, G. A., Teixeira, A. L. & Sato, E. I. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 19, 927–934 (2010).
Balabanian, K. et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J. Immunol. 170, 3392–3400 (2003).
Menke, J. et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J. Am. Soc. Nephrol. 19, 1177–1189 (2008).
Devarapu, S. K. et al. Reprint of “Dual blockade of the pro-inflammatory chemokine CCL2 and the homeostatic chemokine CXCL12 is as effective as high dose cyclophosphamide in murine proliferative lupus nephritis”. Clin. Immunol. 185, 119–127 (2017).
Liao, X., Pirapakaran, T. & Luo, X. M. Chemokines and chemokine receptors in the development of lupus nephritis. Mediators. Inflamm. 2016, 6012715 (2016).
Furuichi, K. et al. Distinct expression of CCR1 and CCR5 in glomerular and interstitial lesions of human glomerular diseases. Am. J. Nephrol. 20, 291–299 (2000).
Yoshimoto, S. et al. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am. J. Kidney Dis. 50, 47–58 (2007).
Nakatani, K. et al. Fractalkine expression and CD16+ monocyte accumulation in glomerular lesions: association with their severity and diversity in lupus models. Am. J. Physiol. Ren. Physiol. 299, F207–F216 (2010).
Biajoux, V. et al. Expression of CXCL12 receptors in B cells from Mexican Mestizos patients with systemic lupus erythematosus. J. Transl. Med. 10, 251 (2012).
Wu, X., Guo, J., Ding, R., Lv, B. & Bi, L. CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice. Acta Histochem. 117, 732–737 (2015).
Inoue, A. et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum. 52, 1522–1533 (2005).
Bignon, A. et al. CCR1 inhibition ameliorates the progression of lupus nephritis in NZB/W mice. J. Immunol. 192, 886–896 (2014).
Cheng, Q. et al. CXCR4-CXCL12 interaction is important for plasma cell homing and survival in NZB/W mice. Eur. J. Immunol. 48, 1020–1029 (2018).
Ble, A. et al. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am. J. Nephrol. 34, 367–372 (2011).
Volkmann, E. R. & Varga, J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat. Rev. Rheumatol. 15, 208–224 (2019).
Denton, C. P. & Ong, V. H. Targeted therapies for systemic sclerosis. Nat. Rev. Rheumatol. 9, 451–464 (2013).
Yamamoto, T. Animal model of systemic sclerosis. J. Dermatol. 37, 26–41 (2010).
Carulli, M. T., Handler, C., Coghlan, J. G., Black, C. M. & Denton, C. P. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Ann. Rheum. Dis. 67, 105–109 (2008).
Torok, K. S. et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin. Arthritis Rheum. 45, 284–293 (2015).
Distler, J. H., Akhmetshina, A., Schett, G. & Distler, O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology 48, 98–103 (2009).
Carulli, M. T. et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum. 52, 3772–3782 (2005).
Carvalheiro, T. et al. Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients. Inflamm. Res. 67, 169–177 (2018).
McCoy, S. S. et al. Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta. Rheumatology 56, 1970–1981 (2017).
Hoffmann-Vold, A. M. et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis. Chest 150, 299–306 (2016).
Lim, J. Y., Ryu, D. B., Lee, S. E., Park, G. & Min, C. K. Mesenchymal stem cells (MSCs) attenuate cutaneous sclerodermatous graft-versus-host disease (Scl-GVHD) through inhibition of immune cell infiltration in a mouse model. J. Invest. Dermatol. 137, 1895–1904 (2017).
Tsou, P. S. et al. Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. Rheumatology 55, 745–754 (2016).
Rabquer, B. J. et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res. Ther. 13, R18 (2011).
van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433–443 (2014).
Cossu, M. et al. Earliest phase of systemic sclerosis typified by increased levels of inflammatory proteins in the serum. Arthritis Rheumatol. 69, 2359–2369 (2017).
Benyamine, A. et al. Increased serum levels of fractalkine and mobilisation of CD34+CD45– endothelial progenitor cells in systemic sclerosis. Arthritis Res. Ther. 19, 60 (2017).
Yamamoto, T. & Nishioka, K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J. Invest. Dermatol. 121, 510–516 (2003).
Arai, M. et al. Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J. Dermatol. Sci. 69, 250–258 (2013).
Watts, R. A. & Scott, D. G. Recent developments in the classification and assessment of vasculitis. Best Pract. Res. Clin. Rheumatol. 23, 429–443 (2009).
Mogi, M. & Liu, S. Animal models of vasculitis. Methods Mol. Biol. 1868, 223–232 (2018).
Miyabe, C. et al. Am80, a retinoic acid receptor agonist, ameliorates murine vasculitis through the suppression of neutrophil migration and activation. Arthritis Rheum. 65, 503–512 (2013).
Dallos, T. et al. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum. 62, 3496–3503 (2010).
Brix, S. R. et al. CC chemokine ligand 18 in ANCA-associated crescentic GN. J Am. Soc. Nephrol. 26, 2105–2117 (2015).
Eriksson, P., Andersson, C., Cassel, P., Nystrom, S. & Ernerudh, J. Increase in Th17-associated CCL20 and decrease in Th2-associated CCL22 plasma chemokines in active ANCA-associated vasculitis. Scand. J. Rheumatol. 44, 80–83 (2015).
Matsunawa, M. et al. Elevated serum levels of soluble CX3CL1 in patients with microscopic polyangiitis. Clin. Exp. Rheumatol. 27, 72–78 (2009).
Blaschke, S., Brandt, P., Wessels, J. T. & Muller, G. A. Expression and function of the C-class chemokine lymphotactin (XCL1) in Wegener’s granulomatosis. J. Rheumatol. 36, 2491–2500 (2009).
Savioli, B., Abdulahad, W. H., Brouwer, E., Kallenberg, C. G. M. & de Souza, A. W. S. Are cytokines and chemokines suitable biomarkers for Takayasu arteritis? Autoimmun. Rev. 16, 1071–1078 (2017).
Dhawan, V., Mahajan, N. & Jain, S. Role of C-C chemokines in Takayasu’s arteritis disease. Int. J. Cardiol. 112, 105–111 (2006).
Samson, M. et al. Involvement and prognosis value of CD8+ T cells in giant cell arteritis. J. Autoimmun. 72, 73–83 (2016).
van Sleen, Y. et al. Involvement of monocyte subsets in the immunopathology of giant cell arteritis. Sci. Rep. 7, 6553 (2017).
Feng, S., Yadav, S. K., Gao, F. & Yi, Q. Plasma levels of monokine induced by interferon-gamma/chemokine (C-X-X motif) ligand 9, thymus and activation-regulated chemokine/chemokine (C-C motif) ligand 17 in children with Kawasaki disease. BMC Pediatr. 15, 109 (2015).
Stock, A. T., Hansen, J. A., Sleeman, M. A., McKenzie, B. S. & Wicks, I. P. GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. J. Exp. Med. 213, 1983–1998 (2016).
Suzuki, C. et al. Non-receptor type, proline-rich protein tyrosine kinase 2 (Pyk2) is a possible therapeutic target for Kawasaki disease. Clin. Immunol. 179, 17–24 (2017).
Samson, M. et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun. Rev. 16, 833–844 (2017).
Martinez, H. G. et al. Important role of CCR2 in a murine model of coronary vasculitis. BMC Immunol. 13, 56 (2012).
Miyabe, C. et al. Dectin-2-induced CCL2 production in tissue-resident macrophages ignites cardiac arteritis. J. Clin. Invest. 130, 3610–3624 (2019).
Jayne, D. R. W. et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 28, 2756–2767 (2017).
Sadik, C. D., Miyabe, Y., Sezin, T. & Luster, A. D. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. Semin. Immunol. 37, 21–29 (2018).
Dalakas, M. C. Inflammatory muscle diseases. N. Engl. J. Med. 373, 393–394 (2015).
Zhu, Z. et al. Altered chemokine receptor expression in the peripheral blood lymphocytes in polymyositis and dermatomyositis. Cytokine 99, 316–321 (2017).
Malmstrom, V., Venalis, P. & Albrecht, I. T cells in myositis. Arthritis Res. Ther. 14, 230 (2012).
Rosenberg, N. L. & Kotzin, B. L. Aberrant expression of class II MHC antigens by skeletal muscle endothelial cells in experimental autoimmune myositis. J. Immunol. 142, 4289–4294 (1989).
Sugihara, T. et al. A new murine model to define the critical pathologic and therapeutic mediators of polymyositis. Arthritis Rheum. 56, 1304–1314 (2007).
Rosenberg, N. L., Ringel, S. P. & Kotzin, B. L. Experimental autoimmune myositis in SJL/J mice. Clin. Exp. Immunol. 68, 117–129 (1987).
De Paepe, B., Creus, K. K. & De Bleecker, J. L. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 21, 610–616 (2009).
Gono, T. et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology 53, 2196–2203 (2014).
De Paepe, B., Creus, K. K. & De Bleecker, J. L. Chemokines in idiopathic inflammatory myopathies. Front. Biosci. 13, 2548–2577 (2008).
Hak, A. E., de Paepe, B., de Bleecker, J. L., Tak, P. P. & de Visser, M. Dermatomyositis and polymyositis: new treatment targets on the horizon. Neth. J. Med. 69, 410–421 (2011).
Suzuki, F. et al. Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activity. Arthritis Res. Ther. 14, R48 (2012).
Suzuki, F. et al. Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice. J. Immunol. 175, 6987–6996 (2005).
Kim, J. et al. Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse. Arthritis Res. Ther. 16, R126 (2014).
De Paepe, B., Creus, K. K. & De Bleecker, J. L. Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann. NY Acad. Sci. 1109, 441–453 (2007).
The work of Y.M. is supported by the Japanese Society for the Promotion of Science (JSPS) Kakenhi grant number JP19K08895, the Takeda Science Foundation, the Maruyama Memorial Research Foundation and the Medical Research Encouragement Prize of the Japan Medical Association. The work of A.D.L. is supported by grants from the National Institutes of Health and the Rheumatology Research Foundation.
The authors declare no competing interests.
Peer review information
Nature Reviews Rheumatology thanks A. Proudfoot, P. Proost and P.P. Tak for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Miyabe, Y., Lian, J., Miyabe, C. et al. Chemokines in rheumatic diseases: pathogenic role and therapeutic implications. Nat Rev Rheumatol 15, 731–746 (2019). https://doi.org/10.1038/s41584-019-0323-6
Recombinant Adiponectin Induces the Production of Pro-Inflammatory Chemokines and Cytokines in Circulating Mononuclear Cells and Fibroblast-Like Synoviocytes From Non-Inflamed Subjects
Frontiers in Immunology (2021)
Immunity, Inflammation and Disease (2021)
Lupus Science & Medicine (2020)
Chemokines as Drivers of the Autoimmune Destruction in Type 1 Diabetes: Opportunity for Therapeutic Intervention in Consideration of an Optimal Treatment Schedule
Frontiers in Endocrinology (2020)